Let’s look at the key reasons that are pushing Acadia Pharmaceuticals Inc (ACAD) to new highs

On Monday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) opened lower -1.53% from the last session, before settling in for the closing price of $16.95. Price fluctuations for ACAD have ranged from $14.15 to $31.92 over the past 52 weeks.

Healthcare Sector giant saw their annual sales surged by 27.73% over the last five years. Company’s average yearly earnings per share was noted 293.22% at the time writing. With a float of $164.30 million, this company’s outstanding shares have now reached $166.35 million.

The firm has a total of 598 workers. Let’s measure their productivity. In terms of profitability, gross margin is 91.61%, operating margin of 12.08%, and the pretax margin is 14.71%.

Acadia Pharmaceuticals Inc (ACAD) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acadia Pharmaceuticals Inc is 1.26%, while institutional ownership is 93.77%. The most recent insider transaction that took place on Nov 19 ’24, was worth 173,630. In this transaction EVP, COO, HEAD OF COMMERCIAL of this company sold 10,329 shares at a rate of $16.81, taking the stock ownership to the 62,105 shares. Before that another transaction happened on Nov 19 ’24, when Company’s PRINCIPAL ACCOUNTING OFFICER sold 4,073 for $16.81, making the entire transaction worth $68,467. This insider now owns 19,863 shares in total.

Acadia Pharmaceuticals Inc (ACAD) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 293.22% per share during the next fiscal year.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators

Check out the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). In the past quarter, the stock posted a quick ratio of 2.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.92. Likewise, its price to free cash flow for the trailing twelve months is 13.37.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 0.76 in one year’s time.

Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)

Analysing the last 5-days average volume posted by the [Acadia Pharmaceuticals Inc, ACAD], we can find that recorded value of 2.07 million was better than the volume posted last year of 1.69 million. As of the previous 9 days, the stock’s Stochastic %D was 46.12%. Additionally, its Average True Range was 0.67.

During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 51.84%, which indicates a significant increase from 15.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.54% in the past 14 days, which was lower than the 37.66% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $16.42, while its 200-day Moving Average is $16.41. Now, the first resistance to watch is $16.83. This is followed by the second major resistance level at $16.96. The third major resistance level sits at $17.12. If the price goes on to break the first support level at $16.54, it is likely to go to the next support level at $16.38. Now, if the price goes above the second support level, the third support stands at $16.25.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats

There are currently 166,392K shares outstanding in the company with a market cap of 2.71 billion. Presently, the company’s annual sales total 726,440 K according to its annual income of -61,290 K. Last quarter, the company’s sales amounted to 250,400 K and its income totaled 32,770 K.